161 related articles for article (PubMed ID: 24681743)
1. Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses.
Bakkar R; Gershenson D; Fox P; Vu K; Zenali M; Silva E
Int J Gynecol Pathol; 2014 May; 33(3):302-8. PubMed ID: 24681743
[TBL] [Abstract][Full Text] [Related]
2. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
[TBL] [Abstract][Full Text] [Related]
3. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Rosendahl M; Høgdall CK; Mosgaard BJ
Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
[TBL] [Abstract][Full Text] [Related]
4. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
[TBL] [Abstract][Full Text] [Related]
5. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall.
Recine MA; Deavers MT; Middleton LP; Silva EG; Malpica A
Am J Surg Pathol; 2004 Dec; 28(12):1646-51. PubMed ID: 15577686
[TBL] [Abstract][Full Text] [Related]
6. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer.
Zeppernick F; Meinhold-Heerlein I
Arch Gynecol Obstet; 2014 Nov; 290(5):839-42. PubMed ID: 25082067
[TBL] [Abstract][Full Text] [Related]
7. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
8. Lymph node-positive stage IIIC ovarian cancer: a separate entity?
Berek JS
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S18-20. PubMed ID: 19955908
[TBL] [Abstract][Full Text] [Related]
9. Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors).
Fadare O
Int J Gynecol Cancer; 2009 Jan; 19(1):103-8. PubMed ID: 19258950
[TBL] [Abstract][Full Text] [Related]
10. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
11. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
12. Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study.
Hjerpe E; Staf C; Dahm-Kähler P; Stålberg K; Bjurberg M; Holmberg E; Borgfeldt C; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E
Acta Oncol; 2018 Mar; 57(3):331-337. PubMed ID: 29130381
[TBL] [Abstract][Full Text] [Related]
13. Lymphovascular space invasion and Ki67 as predictors of lymph node metastasis in primary low grade serous ovarian cancer.
Grabowski JP; Glajzer J; Richter R; Plett H; Muallem MZ; Braicu EI; Taube E; Sehouli J
Int J Gynecol Cancer; 2021 Jan; 31(1):98-103. PubMed ID: 33127866
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of lymph node involvement in ovarian serous borderline tumors.
Lesieur B; Kane A; Duvillard P; Gouy S; Pautier P; Lhommé C; Morice P; Uzan C
Am J Obstet Gynecol; 2011 May; 204(5):438.e1-7. PubMed ID: 21349494
[TBL] [Abstract][Full Text] [Related]
15. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
[TBL] [Abstract][Full Text] [Related]
16. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry.
Mattes MD; Lee JC; Metzger DJ; Ashamalla H; Katsoulakis E
J Gynecol Oncol; 2015 Jan; 26(1):19-24. PubMed ID: 25310855
[TBL] [Abstract][Full Text] [Related]
17. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
18. Comparison of survival outcomes in optimally and maximally cytoreduced stage IIIC ovarian high-grade serous carcinoma: Women with only peritoneal tumor burden versus women with both peritoneal and lymphogenous dissemination.
Selcuk I; Meydanli MM; Yalcin I; Gungorduk K; Akgol S; Çelik H; Ayhan A
J Obstet Gynaecol Res; 2019 Oct; 45(10):2074-2081. PubMed ID: 31373110
[TBL] [Abstract][Full Text] [Related]
19. ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers.
Li Y; Fei H; Lin Q; Liang F; You Y; Li M; Wu M; Qu Y; Li P; Yuan Y; Chen T; Jiang H
Oncogene; 2021 Aug; 40(32):5131-5141. PubMed ID: 34211089
[TBL] [Abstract][Full Text] [Related]
20. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
Khalifeh I; Munkarah AR; Lonardo F; Malone JM; Morris R; Lawrence WD; Ali-Fehmi R
Int J Gynecol Pathol; 2004 Apr; 23(2):162-9. PubMed ID: 15084845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
